4 Immunotherapies to Watch

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Boosting the immune system to fight disease isn't revolutionary. Research has shown that the chicken soup your mom gave you when you were sick actually helped your immune system rid your body of whatever was making you feel under the weather. Merck's (NYSE: MRK  ) PegIntron and Roche's Pegasys work by giving patients' immune systems a boost to help them fight off the hepatitis C virus.

But lately companies have taken the idea of using the immune system a bit further to include fighting cancer. The idea sounds simple enough, but since the immune system has been trained to only attack foreign cells and viruses, it can be a little tricky depending on the tumor type.

For melanoma -- aka skin cancer -- it turns out that pumping up the immune system is enough to help patients. In March, both Merck's PegIntron -- branded as Sylatron for cancer -- and Bristol-Myers Squibb's (NYSE: BMY  ) Yervoy were approved as a treatment for melanoma.

The two drugs work in different ways but produce the same effect. Sylatron stimulates the production of immune cells while Yervoy inhibits a protein that inhibits the immune cells; inhibit an inhibitor, and you get a positive reaction.

Getting specific
In contrast to the general immune system promoters, Dendreon's (Nasdaq: DNDN  ) Provenge encourages the immune system to attack a specific type of cell -- in this case prostate cancer cells. It's often called a cancer vaccine, but it's not the traditional type of vaccine that you get to keep from being sick. Instead, Provenge is used after a patient has prostate cancer to train the immune system, and it's a little more complicated than a jab in the arm.

To produce Provenge, immune cells are taken from a patient and sent to a processing plant where they're exposed to an antigen that's present on the prostate cancer cells. The immune cells are then put back into the patient where they train the rest of the immune system to attack the prostate cancer cells.

The next Provenge
There are a bunch of companies trying to develop immunotherapies.

Oncothyreon (Nasdaq: ONTY  ) is developing Stimuvax, which trains the immune system to target the MUC-1 protein. The drug, which is in a pivotal phase 3 trial in lung cancer, is backed by Merck KGaA.

Likewise, CEL-SCI (AMEX: CVM  ) has the backing of Teva Pharmaceuticals (Nasdaq: TEVA  ) in the development of its cancer therapy Multikine as a treatment for head and neck cancer. The pivotal study just began at the end of last year, so investors will have to wait awhile to see if the drug works.

GlaxoSmithKline has a cancer vaccine, MAGE-A3 ASCI, which homes the immune system in on the MAGE-A3 protein that's present on lung cancer cells. The company has hooked up with Abbott Labs (NYSE: ABT  ) to develop a companion diagnostic that determines if the tumor expresses the MAGE-A3 protein.

And Dendreon is looking to expand into other cancer types by using the same system as Provenge, but different antigens to train the immune system to attack tumors of different origins. Next up: DN24-02 in bladder cancer.

Not a sure thing
While the success of Yervoy and Provenge should give investors confidence that the approach is working, it's still far from a sure thing. There's no guarantee that an antigen will actually stimulate the immune system enough to inflict any real damage on the tumor. It's also possible for an overreaction to occur, causing the immune system to attack cells it really shouldn't. Dendreon is likely the safest bet here since its technology is already proven to work in at least one cell type.

The backing of large companies Merck KGaA, Teva, and Glaxo is certainly a plus -- at least someone with drug-development experience thinks it's worthy of an investment. But keep in mind that the immunotherapies are just one of many drugs in their pipelines. If you're going to invest in this high-risk space, I'd suggest you do the same.

Looking for more stock ideas? Here are five stocks that The Motley Fool owns, and its analysts think you should, too.

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of GlaxoSmithKline, Teva Pharmaceutical Industries, and Abbott Laboratories. Motley Fool newsletter services have recommended buying shares of Abbott Laboratories, GlaxoSmithKline, and Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (3) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 29, 2011, at 3:44 PM, soho48 wrote:

    You failed to mention IMUC, much like DNDN, they use the immune system to hunt out cancer stem cells. Early results are promising. Cheap and speculative.

  • Report this Comment On June 29, 2011, at 6:43 PM, Pablokruise wrote:

    Yes, IMUC is a Great "speculative" buy.

    I have a good "feeling" about them and think the Upside potential is Huge, easily 20X if they make it out of the "FDA" approval cycle.

    A little safer bet with still good upside potential is Biogen "BIIB". Recently doing a nice break out move over it's 100 day moving average.

    Or play it safer yet and buy into one of the best ETF's for Biotechs: "FBT".

  • Report this Comment On July 08, 2011, at 5:46 PM, nycabman wrote:

    Brian, Regarding CelSci. Would it be appropriate for the company or anyone working on the trial to report interim results ? For example, if there is measureable tumor reduction? Or if as the CEO previously stated, patients have increased movement of their tongue? Won't this be reported prior to the end of the trial? Yes, I understand the FDA protocol is looking for 3 year results, but as I understand it, many trials are halted for humanitarian resons if efficasy is established far earlier than expected.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1513565, ~/Articles/ArticleHandler.aspx, 10/23/2016 4:13:05 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
ABT $40.50 Down -0.24 -0.59%
Abbott Laboratorie… CAPS Rating: *****
BMY $50.02 Down -0.34 -0.68%
Bristol-Myers Squi… CAPS Rating: ****
CVM $0.24 Up +0.04 +16.99%
CEL-SCI CAPS Rating: **
DNDNQ $0.00 Down +0.00 +0.00%
Dendreon Corp CAPS Rating: *
MRK $61.20 Down -0.72 -1.16%
Merck and Co. CAPS Rating: ****
ONTY.DL $1.06 Down -0.02 -1.85%
Oncothyreon CAPS Rating: ****
TEVA $44.00 Down -0.21 -0.48%
Teva Pharmaceutica… CAPS Rating: ****